Axitinib
Chemical compound
Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
Nº Q4830631 ★
Common · Knowledge
Axitinib
Chemical compound
Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
Last price
—
Floor price
—
7-day median
—
30-day sales
0
30-day range
—
In circulation
0
Price history
median
low – high
sales
No sales in this period
Show table
| Date | median | Low | High | sales |
|---|
Sales history
- Last sale
- —
- 30-day average
- —
- 30-day low
- —
- 30-day high
- —
- Sales 7d
- 0
- Sales 30d
- 0
No sales yet.
Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.
From Wikipedia
Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. It was approved to treat renal cell carcinoma by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival, though there have been reports of fatal adverse effects.
Text: Wikipédia, CC BY-SA 4.0. · Image: Vaccinationist (CC BY-SA 4.0) ·
Related cards
Sunitinib
Chemical compound
Nº Q417542 ★
Upadacitinib
Chemical compound
Nº Q27074125 ★★
Acitretin
Chemical compound
Nº Q341500 ★
Cetuximab
Pharmaceutical drug
Nº Q420296 ★
Osimertinib
Chemical compound, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, used as a medication to treat non-small-cell lung carcinomas with a specific mutation
Nº Q21506464 ★
Secukinumab
Monoclonal antibody against IL-17 used for treatment of psoriasis
Nº Q7444755 ★★